SCHEMBL6670125

SCHEMBL6670125

COc1ccc(CN2Cc3c(-c4ccccc4Cl)cc(S(=O)(=O)N4CCNCC4C)cc3N(c3c(Cl)cccc3Cl)C2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.42
CHRM5 P08912 1/20 0.39
CASP3 P42574 4/20 0.36
CASP7 P55210 4/20 0.36
MMP1 P03956 2/20 0.36
MMP3 P08254 2/20 0.36
MMP7 P09237 2/20 0.36
MMP9 P14780 2/20 0.36
LMNA P02545 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
MMP13 P45452 1/20 0.36
MAPK13 O15264 1/20 0.34
MAPK12 P53778 1/20 0.34
MAPK11 Q15759 1/20 0.34
MMP2 P08253 1/20 0.34
MMP8 P22894 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6666877 0.86 MAPK14 (0.42) MAPK14CHRM5CASP3CASP7LMNA
SCHEMBL6644394 0.84 MAPK14 (0.48) MAPK14CHRM5CASP3LMNAALDH1A1
SCHEMBL6669384 0.82 MAPK14 (0.43) MAPK14CHRM5CASP3CASP7LMNA
SCHEMBL6672918 0.82 MAPK14 (0.40) MAPK14CHRM5CASP3CASP7MMP1
SCHEMBL6668537 0.80 ALDH1A1 (0.43) MAPK14CHRM5LMNAALDH1A1TSHR
SCHEMBL6669517 0.79 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6642728 0.79 MAPK14 (0.38) MAPK14MMP1MMP3MMP7MMP9
SCHEMBL6667226 0.78 MAPK14 (0.51) MAPK14CHRM5TSHR
SCHEMBL6667945 0.78 MAPK14 (0.53) MAPK14CHRM5TSHR
SCHEMBL6668236 0.76 MAPK14 (0.50) MAPK14CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6809199-B2 ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES MERCK & CO., INC. 2004-10-26 US disclosed
EP-1345603-A4 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO INC (US) 2004-09-08 EP disclosed
EP-1345603-A1 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS Merck & Co., Inc. (US) 2003-09-24 EP disclosed
WO-2002058695-A9 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO INC (US) 2003-09-12 WO disclosed
US-20030092712-A1 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents MERCK SHARP & DOHME CORP. 2003-05-15 US disclosed
WO-2002058695-A1 (HALO-BENZO CARBONYL)HETEROCYCLO FUSED PHENYL P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092712-A1 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents MAPK1, MAPK7, MAPKAPK2 MAPK14 5/4885CHRM5 4865/4885CASP3 3149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.